News & Updates

Show Multimedia Only
Upadacitinib proves long-term efficacy in RA

Upadacitinib proves long-term efficacy in RA

17 Jul 2024 byStephen Padilla

Upadacitinib remains effective through 5 years in patients with rheumatoid arthritis (RA) who have inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), with no new safety signals, as shown by the results of the phase III long-term extension (LTE) of SELECT-NEXT.

Upadacitinib proves long-term efficacy in RA

17 Jul 2024
Reduced kidney function after stroke ups risk of recurrence, dementia

Reduced kidney function after stroke ups risk of recurrence, dementia

17 Jul 2024
INHALE-3 underpins alternate insulin delivery method for T1D

INHALE-3 underpins alternate insulin delivery method for T1D

17 Jul 2024